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Abstract
Background: A new disease class of syndromes, described as linkeropathies, which are derived from defects in the
glycosaminoglycan-linker region as well as glycosaminoglycan-side chains of proteoglycans is increasingly being
recognized as a cause of human disease. Proteoglycans are an essential component of the extracellular matrix.
Defects in the enzymatic process of proteoglycan synthesis broadly occur due to the incorrect addition of side
chains. Previously, homozygous missense variants within the B3GAT3 gene encoding beta 1,3 glucuronyltransferase
3(GlcAT-I) responsible for the biosynthesis of glycosaminoglycans have been described in 7 individuals.
Case presentation: In this study, a 4-year-old patient with a severe phenotype of osteoporosis, hypotonia, joint
laxity, fractures, scoliosis, biscuspid aortic valve and myopia was referred for next generation sequencing after
extensive negative clinical testing. Whole exome sequencing was performed on the proband and his unaffected
parents to identify the molecular basis of his disease. Sequencing revealed compound heterozygous variants in
B3GAT3: c.1A > G (p.Met1?) and c.671 T > A (p.L224Q). Clinical and in vitro functional studies were then completed
to verify the pathogenicity of the genotype and further characterize the functional basis of the patient’s disease
demonstrating the patient had a decrease both in the protein level of B3GAT3 and in the glucuronyltransferase
activity when compared to control samples. Independent in vitro assessment of each variant confirmed the B3GAT3:
c.1A > G (p.Met1?) variant is functionally null and the c.671 T > A (p.L224Q) missense variant has significantly
reduced glucuronyltransferase activity (~3% of control).
Conclusions: This is the first report of a patient with compound heterozygosity for a null variant in trans with a
missense in B3GAT3 resulting in a severe phenotype, expanding both the genotypic and phenotypic spectrum of
B3GAT3-related disease.
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Background
A new class of syndromes, described as linkeropathies,
which encompass defects in the glycosaminoglycan
(GAG)-linker region as well as GAG-side chains of pro-
teoglycans is increasingly being recognized as the cause
of human disease [1, 2]. Proteoglycans are an essential
component of extracellular matrix, particularly in cartil-
age, bone and the cardiovascular system [3–5]. They
consist of a core protein produced in the endoplasmic
reticulum, with a linker region that is added in the endo-
plasmic reticulum and Golgi apparatus [6]. The addition
of disaccharide units, epimerisation and sulfation by
various glycosyltransferases, sulfotransferases, and epim-
erases result in the biosynthesis of GAG side chains in-
cluding heparan, chondroitin, and dermatan sulfates of
proteoglycans [1, 7, 8]. Defects in any step of the enzym-
atic process of proteoglycan synthesis cause a decrease
in mature GAGs [1, 2, 7]. Specifically, B3GAT3, beta-
1,3-glucuronyltransferase 3 (glucuronosyltransferase I,
GlcAT-I), encodes a glycosyltransferase that functions to
add the final glucuronic acid in the linker region tetra-
saccharide, xylose-galactose-galactose-glucuronic acid,
which is attached to specific serine residues on core pro-
teins [9, 10]. Variants in B3GAT3 (Larsen Syndrome,
OMIM #245600), as well as B3GALT6 (Spondyloepime-
tapyseal Dysplasia with Join Laxity, OMIM # 271640),
B4GALT7 (Ehlers-Danlos syndrome with short stature
and lim anomalies, OMIM #130070), and XYLT1 (Des-
buquois dysplasia-2, OMIM #615777) have been associ-
ated with linkeropathies, which are broadly associated
with joint laxity, fractures, and cardiac malformations
[11–14]. However, these are a relatively new class of dis-
orders, therefore it is unlikely the phenotypic spectrum
has been fully recognized. Specifically, for B3GAT3, only
7 individuals, all with homozygous missense variants
have been described ranging in phenotypic severity from
mild to severe, with all patients having congenital heart
defects, joint hypermobility, and fractures [11, 15–17].
Herein we describe the first patient with compound
heterozygosity for a null variant in trans with a missense
in B3GAT3 identified as the cause of disease and provide
functional characterization.
Materials and methods (See Additional file 1:
Supplemental Information for Detailed Methods)
Whole exome sequencing
Samples were prepared for whole exome sequencing
using the Nextera Rapid Capture Exome Kit (Illumina,
San Diego, CA) according to manufacturer’s protocols.
Sequencing was completed on an Illlumina HiSeq 2500
instrument with TruSeq v4 reagents, yielding paired end
125 nucleotide reads, with an average of 12.7 GB of data
resulting in a mean 66× coverage. Gapped alignment to
reference sequences (GRCh37.p5) was performed with
GSNAP and the GATK and analysis completed using
custom-developed software, RUNES and VIKING as
previously reported [18, 19].
Cell culture
Fibroblasts for cmh000720 utilized in the current studies
were obtained when the patient was approximately
5 months old. Age- and sex- matched control fibroblasts
were used for the functional assays.
Western blotting
Twenty micrograms of fibroblast cell lysate of patient
and matched control were separated on a 10% SDS-PA
gel. Primary anti-B3GAT3 antibody (Abnova, Atlanta,
GA) was for staining. As an additional loading control
experiment, membranes were stripped and stained with
anti-actin antibody (1:5000, polyclonal mouse; BD
Bioscience).
qPCR
RNA was isolated from confluent primary fibroblast cul-
tures using Trizol (Ambion/Thermo Fisher, Grand Is-
land, NY). B3GAT3 mRNA levels were analyzed in
primary fibroblasts by quantitative PCR (qPCR) using
the ProtoScript® First Strand cDNA Synthesis Kit (NEB,
Ipswich, MA). Two sets of intron spanning primers were
designed for B3GAT3 mRNA (Additional file 1: Table
S1) and GAPDH was used as an endogenous control.
Relative expression was determined using the 2 −ΔΔCt
method [20].
GlcAT-I assay of the recombinant wild-type and mutant,
L224Q, GlcAT-I proteins
The expression vector of human GlcAT-I (wild-type),
p3xFLAG-CMV8/hGlcAT-I, was used as described pre-
viously [11], and the mutant vector was constructed by
overlapping extension PCR method [21]. Each vector
was transiently transfected into HEK293T cells using the
FuGENE HD DNA-transfection reagent (Promega,
Madison, WI, USA). Three days after transfection, an
aliquot of the conditioned media was individually incu-
bated with an anti-FLAG affinity agarose resin (Wako,
Osaka, Japan) at 4 °C for 4 h. To examine the expression
of both recombinant enzymes, SDS-PAGE and western
blotting were performed using an anti-FLAG antibody.
Glucuronyltransferase activity was examined as de-
scribed previously [11]. Briefly, the enzyme-bound resin
as an enzyme source, UDP-[14C]-GlcA (Perkin Elmer,
Boston, MA, USA) as the sugar donor substrate, and
Galβ1-3Galβ1-O-methyl (Sigma, St. Louis, MO, USA) as
the sugar acceptor were utilized for the assay. The reac-
tion mixtures were incubated at 37 °C for 20 min. The
radiolabeled products were separated from UDP-[14C]-
GlcA using anion-exchange resin, AG 1-×8 (PO4
2− form),
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as described previously [22]. The isolated products,
[14C]-GlcAβ1-3Galβ1-3Galβ1-O-methyl, were quantified
in a liquid scintillation counter (LSC-7400, Hitachi-
Aloka, Tokyo, Japan).
Comparison of the GlcAT-I activities of fibroblast
homogenates
The homogenates of the fibroblasts were assayed using
Galβ1-3Galβ1-O-methyl as an acceptor (220 nmol) and
UDP-[14C]-GlcA as a donor substrate, and then incu-
bated for 4 h at 30 °C. The procedures thereafter were
described above.
Cell-based ELISA
Cell-based ELISA was carried out using the protocol pro-
vided by R&D Systems Inc. (https://www.rndsystems.com/
products/cell-based-elisas) with slight modifications.
Briefly, fibroblasts from the patient and a control subject
were cultured to determine the amount of CS. Cells were
washed and treated with chondroitinase ABC at 37 °C for
30 min. After washing the chondroitinase-treated cells
were fixed, incubated with the primary antibodies, a mix-
ture of commercial anti-CS-stub antibodies (1B5, 2B6,
and 3B3) (Cosmo Bio Co., LTD, Tokyo, Japan). Subse-
quently the cells were incubated with a secondary anti-
body, alkaline phosphatase-conjugated anti-mouse IgG.
Finally, the cells were incubated with the substrate, p-ni-
trophenyl phosphate, and analyzed by measuring the ab-
sorbance at 405 nm with an iMark microplate absorbance
reader (Bio-Rad, Hercules, CA, USA).
Characterization of the mutation in start codon of GlcAT-I
An expression vector of the C-terminally GFP-tagged
human GlcAT-I, pAcGFP-hGlcAT-I (wild-type), was
constructed. To examine the effects of variants in the
start codon of GlcAT-I on the expression of the encoded
proteins, mutant vectors were constructed in frame with
C-terminal GFP tag. Each vector was transiently trans-
fected into HEK293T as described above. To examine
which ATG is utilized as the initiation codon, SDS-
PAGE and western blotting were performed using an
anti-GFP antibody, mFX75 (Wako, Japan).
Case presentation
The patient, cmh000720, is currently a 6-year-old male
who was referred for whole exome sequencing at 4 years
of age. The patient was conceived via artificial insemin-
ation and was born at an estimated 38 weeks gestation via
C-section to a 32-year-old G3P2 mother and distantly re-
lated 27-year-old father (5th cousins once removed). The
pregnancy was complicated by gestational diabetes that
was well managed with diet. Decreased fetal movements
were noted throughout pregnancy, however the results
from ultrasound exams and maternal serum AFP testing
were normal. At birth the patient was noted to have a
week cry, hypotonia, joint hypermobility, and an undes-
cended testicle. Apgar scores were 8 and 9 at 1 and 5 min
respectively; weight was 3.1 kg (30th%ile) and length
50.8 cm (68th%ile). He was discharged home at 2 days of
life. Newborn screening was reported to be normal. At a
routine pediatric follow up appointment at two weeks of
age the patient was hospitalized for additional evaluation
due to concerns of his persistent low tone and cardiac
murmur. At that time he was noted to have both a left hip
dislocation and right hip subluxation, with bilateral ace-
tabular dysplasia. Use of a Pavlik harness failed correct the
hip dislocation due to profound ligamentous laxity. Echo-
cardiogram revealed a PFO and biscupid aortic valve. The
patient had inconsistent TSH levels and thus was treated
with levothyroxine. An MRI was suggestive of an arach-
noid cyst, but was otherwise unremarkable. At 2.5 months
of age an EEG revealed abnormal sharp waves, and CSF
glucose levels were found to be 38. Due to a concern for a
GLUT1 deficiency, a ketogenic diet was trialed but discon-
tinued after the patient became lethargic on the diet and
repeat testing was normal. The patient has had no docu-
mented clinical seizure activity.
In addition to his hip dysplasia, cmh000720 was also
noted to have significant kyphoscoliosis and osteopenia by
4 months of age. He has had multiple fractures associated
with little to no trauma including his left tibia (12 months),
right femur (19 months), right tibia (20 months), left
femur (2.5 years), right femur shaft (3.75 years), distal
right femur (3.8 years), and left femur (4.2 years). Pami-
dronate infusions were trialed but an increase in fractures
was noted. He has significant osteoporosis; bone density
by dexa of the left forearm at 4 years of age was measured
as Z score of -5.8. Spinal fusion rods were placed at 3 years
of age and removed at 5 years of age. He is currently in a
hard brace. Stabilization rods were also placed in both fe-
murs (Fig. 1a).
The patient had developmental delay of gross motor
milestones; currently he is able to walk with a walker and
bear weight but cannot walk independently. Cognitively
he is normal; he was able to say single words at 12 months
and currently only has problems with articulation. At
6 years of age, in addition to the aforementioned symp-
toms, the patient is followed for mild aortic root and as-
cending aorta dilation, restrictive lung disease requiring
C-PAP/BiPAP due to scoliosis and chronic obstructive
pulmonary disease, bilateral hyperopia, astigmatism, am-
blyopia, and mild left ptosis, and hypoglycemia with ill-
ness. His weight 24.76 kg (85th%ile) and length 111 cm
(13th%ile) are within normal limits, although he still re-
ceives supplemental nutrition overnight through a G-tube
that was placed at 20 months of age. He is macrocephalic
with an OFC of 54.8 cm (>98th%ile). He is only mildly dys-
morphic with downslanting palpebral fissures, bluish/grey
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sclera, a high arched palate, short neck, arachnodactyly,
and hyperextensible skin with no striae (Fig. 1b). His bone
age is estimated at 4 years 6 months (>2 SD below ex-
pected for chronological age). He completed kindergarten
with an IEP that includes occupational, speech and phys-
ical therapies.
The family history is notable for an older brother who
was found to have a biscuspid aortic valve, after recom-
mended screening. He has a healthy younger sister. Echo-
cardiograms of both parents and younger sister were
normal. Both parents are tall, and reportedly healthy.
Results
Prior to whole exome sequencing, the patient had extensive
biochemical and genetic testing all of which were normal
or non-diagnostic. Whole exome sequencing of the patient
and both parents revealed compound heterozygous variants
in B3GAT3: a paternally inherited c.1A >G (p.Met1?) and
maternally inherited c.671 T >A (p.L224Q). Subsequent
Sanger sequencing of both siblings revealed that the older
brother who also has a biscuspid aortic valve did not inherit
either variant while the younger sister is heterozygous for
the c.1A >G (p.M1?) variant (Additional file 1: Figure S1).
While the c.1A >G variant has not been reported in any
public database and is unique to the family in an internal
database, a different variant at the same position has been
reported in 2 heterozygous individuals in ExAC (2/62,938).
This variant is predicted to result in loss of translation initi-
ation and was interpreted as likely pathogenic according to
current ACMGG guidelines [23].
Fig. 1 a X-rays revealed severely diffusely demineralized bones, along with multiple growth arrests lines. Stabilization rods are in both femurs and
bilateral bowing of the tibiae and fibulae are evident (right pictured). b Cmh000720 is mildly dysmorphic with downslanting palpebral fissures
(left), short neck, and curved lower extremities. While able to ambulate with a walker and physical assistance, he is wheelchair-bound. c mRNA
expression of B3GAT3 in primary fibroblasts in cmh000720 was not statistically different from control using two sets of primers, whereas western
blotting (d) showed a decrease in overall protein. e Glucuronyltransferase activity was determined by incorporation of [14C]GlcA into the Galβ1-
3Galβ1-O-methyl. The control sample utilized an enzyme source from the fibroblasts from a healthy control subject. *P < 0.0001
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The maternally inherited c.671 T > A (p.L224Q) vari-
ant is in exon 4 and replaces a nonpolar leucine residue
with a polar glutamine residue, a moderate physico-
chemical difference. The leucine is conserved across spe-
cies (Additional file 1: Figure S2); and is predicted to be
disease causing. The variant has not been reported in
any public databases and is unique to the family in an
internal database. Of note, a homozygous variant,
G223S, has been reported in a child with a severe pres-
entation of disease [16]. In the absence of further data,
this variant was interpreted as a variant of unknown sig-
nificance, however, as the patient’s phenotype was con-
sistent with a diagnosis of B3GAT3-related disease,
functional studies were pursued to further characterize
the patient’s disease and novel variants.
To access the overall function of GlcAT-I, western
blotting and expression analyses were performed using
cultured primary fibroblasts from the patient and a
healthy control. No difference in expression was de-
tected in mRNA levels using two different primer pairs
encompassing the first (Fragment A) and second (Frag-
ment B) potential start codon (Fig. 1c, Additional file 1:
Table S1). However western blotting demonstrated a sig-
nificant decrease in protein levels (Fig. 1d). To examine
glucuronyltransferase activity, assays of GlcAT-I activity
were carried out using a cell lysate derived from the pa-
tient’s fibroblast cells. In stark comparison to control
cells, no GlcAT-I activity was detected when lysate from
the patient’s fibroblast cells was used as an enzyme
source (Fig. 1e).
To further examine the effect of p.M1? and p.L224Q
variants independently, wild-type and mutant vectors
were constructed and glucuronyltransferase activity of
the recombinant enzymes was tested. The GlcAT-I-
L224Q construct showed a marked reduction to ~3% of
the wild-type (Fig. 2a). However, protein levels were
comparable to wild-type based on the western blotting
(Fig. 2a). These results suggest that the L224Q variant
affects the glucuronyltransferase activity and the biosyn-
thesis of GAGs including chondroitin sulfate, dermatan
sulfate, and heparan sulfate, and/or their proteoglycan
forms.
To characterize the effects of the variant of the initi-
ation codon on the encoded protein and to determine
which alternative ATG may be utilized as the initiation
codon in the open reading frame of the p.M1? gene,
western blotting of C-terminally GFP-tagged mutant
GlcAT-I proteins in all the possible reading frames
(Additional file 1: Figure S4) was performed. Of note,
there is not an in-frame alternative Met codon upstream
of the Met1, therefore the c.1A > G variant is not pre-
dicted to result in an extended protein. Wild-type
GlcAT-I was detected at a molecular weight of ~64 kDa
(Fig. 2b). Although no obvious mutant proteins (No. 1 ~
3, 5, 7, and 8) of GlcAT-I were detected, GFP-tagged
mutant proteins, #4 as well as #6, were clearly detected
(Fig. 2b). These results indicate that the third and fifth
ATGs of the open reading frame, at the positions of
c.233 and c.584 in mutant B3GAT3 might be utilized, re-
spectively, to initiate translation (Additional file 1: Figure
S3 and Additional file 1: Figure S4, Additional file 1:
Table S2). The resultant proteins bear a sequence totally
unrelated to the GlcAT-I enzyme, thus the allele (not
the proteins) is considered functionally null.
After confirming the p.M1? variant was functionally
null, to analyze how the reduced activity of GlcAT-I
from the p.L224Q variant affects the biosynthesis of
chondroitin sulfate (CS) side chains of proteoglycans,
the relative numbers of CS chains were analyzed by cell-
based ELISA with three kinds of anti-CS-stub antibodies
using fibroblast cells from the patient and control. These
antibodies can be used as probes for investigating the
relative numbers of CS chains on the core proteins of
proteoglycans [11]. CS-stub antibodies showed a mark-
edly reduced binding to the patient cells compared to
control subject (Fig. 2c), suggesting that the number of
CS chains was significantly reduced in the fibroblast
cells from the patient.
Discussion
We have described the first patient of northern Euro-
pean descent with compound heterozygous variants in
B3GAT3, expanding the phenotypic and genotypic
spectrum associated with disease. Consistent with all pa-
tients reported to have B3GAT3-related disease,
cmh000720 has a cardiac defects, joint laxity, disloca-
tions, contractures, broad tips of fingers and a short
neck [11, 15–17]. Our patient’s features overlap with
those of a patient with severe disease associated with a
homozygous G223S variant; including multiple fractures,
arachnodactyly, and blue sclerae. He did not have a dia-
phragmatic hernia or small thorax, but does have re-
strictive lung disease requiring C-PAP/BiPAP at night.
However, unlike other reported patients, our patient
does not have short stature, currently his height is at the
13th%ile. Additionally, cmh000720 has macrocephaly,
hypothryoidism and hypoglocemia, which have not been
previously reported (Additional file 1: Table S3).
Independent in vitro studies demonstrated the p.M1?
variant is functionally null and the p.L224Q variant has
glucuronosyltransferase activity ~3% of wild-type. Both
of cmh000720’s parents are healthy and no disease
phenotype has been reported to date [11, 16, 17]. Con-
sistent with the reported human phenotypes; null mice
were embryonic lethal while heterozygous mice did not
have a phenotype and were born at Mendelian frequen-
cies [24]. Taken together, the data indicate that 50% glu-
curonosyltransferase activity compared to wild-type is
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Fig. 2 a Glucuronyltransferase activity of each enzyme protein was examined using the partially purified recombinant enzymes, UDP-[14C]-GlcA as
the donor substrate, and Galβ1-3Galβ1-O-methyl as the acceptor substrate. Glucuronyltransferase activity was determined by incorporation of
[14C]GlcA into the Galβ1-3Galβ1-O-methyl. “Mock” indicates the enzyme source from the HEK293T cells transfected with an empty vector. Values
are the means ± SE (n = 3). *P < 0.0005 versus wild-type was calculated by the ANOVA Dunnett test. Two sets of the mutant enzyme, L224Q, were
prepared from two separate conditioned media from the HEK293T cell cultures (left). The purified recombinant GlcAT-I separated by SDS-PAGE was
detected with the horseradish peroxidase-conjugated anti-FLAG antibody (Wako). The broad signals of the FLAG-tagged GlcAT-I may indicate the
N-glycosylated enzymes (~40 kDa). Western blotting analysis showed the expression of comparable amounts of these recombinant proteins.
(right). b The GFP-tagged GlcAT-I and its mutant proteins separated by SDS-PAGE were detected with anti-GFP antibody and the horseradish
peroxidase-conjugated anti-mouse IgG antibody as the primary and secondary antibodies, respectively. The deduced molecular masses of GFP-tagged
wild-type GlcAT-I and the mutant proteins (mutants #1 ~ 8) were summarized in Additional file 1: Table S2. Although no obvious mutant
proteins (No. 1 ~ 3, 7, and 8) of GlcAT-I were detected, GFP-tagged mutant proteins, #4 as well as #5 or 6, were clearly detected.
Predicted molecular weights of the bands of #5 and #6 were 40.2 and 31.3 kDa, respectively (Additional file 1: Table S2). The GFP-tagged mutant
protein #5 or 6 was detected at a molecular weight of ~ 30 kDa, suggesting that the observed GFP-tagged mutant protein might be mutant-#6 rather
than mutant-#5. c Comparison of the amount of CS chains on the cell surface of fibroblasts from the patient and a healthy control by cell-based
ELISA. *P < 0.0001
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sufficient for a normal phenotype. Further studies are
needed to correlate the level of residual activity to result-
ing phenotype.
The cause of endocrine abnormalities in cmh000720 is
not clear. Congenital hypothryoidism is relatively com-
mon, affecting ~1/2000 births. However, thyroid hor-
mone has been shown to play a role in the expression of
proteoglycans and so it cannot be ruled out that the pa-
tient’s B3GAT3 disease is the underlying cause [25].
Similarly, hypoglycemia has not been reported in other
patients. Previous studies have demonstrated a decrease
in chondroitin sulfate and heparan sulfate in patients
with diabetes [26], therefore it is possible that the overall
decrease in GAGs is contributing to his hypoglycemia.
Conclusion
The linkeropathies are still a relatively new class of disor-
ders, with the full disease spectrum yet to be defined.
However, they should be considered as the differential
diagnosis of patients with hypotonia, joint laxity, congeni-
tal heart disease and fractures. It is clear from the limited
case reports to date that there is a wide spectrum of clin-
ical severity associated with disease. As whole exome se-
quencing is quickly becoming the standard for clinical
testing, these patients will likely be diagnosed earlier in
their disease course. Further studies of additional patients
are needed in order to fully elucidate the phenotypic
spectrum and disease mechanisms of these disorders.
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